• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-X filed by BioHarvest Sciences Inc.

    3/31/25 5:12:15 PM ET
    $BHST
    Get the next $BHST alert in real time by email
    F-X 1 bhs_fx.htm APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING Appointment of agent for service of process and undertaking

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM F-X

     

    APPOINTMENT OF AGENT FOR SERVICE OF

    PROCESS AND UNDERTAKING

     

    A.Name of issuer or person filing ("Filer"):BioHarvest Sciences Inc. 

     

    B.(1)This is (check one): 

     

    ☒An original filing for the Filer. 

     

    ☐An amended filing for the Filer. 

     

    (2)Check the following box if you are filing the Form F-X in paper in accordance with Regulation S-T Rule 101(b)(9) ☐ 

     

    C.Identify the filing in conjunction with which this form is being filed: 

     

    Name of registrant:BioHarvest Sciences Inc. 

    Form type:Form 40-F 

    File number (if known):001-42389 

    Filed by:BioHarvest Sciences Inc. 

    Date filed (if filed concurrently, so indicate):March 31, 2025 (filed concurrently) 

     

    D.The Filer is incorporated or organized under the laws of British Columbia, Canada, and has its principal place of business at: 

     

    BioHarvest Sciences Inc.

    1140-625 Howe Street

    Vancouver, British Columbia V6C 2T6, Canada

    +1 (604) 689-5722

     

    E.Filer designates and appoints Empire Stock Transfer Inc. ("Agent"), located at 1859 Whitney Mesa Dr., Henderson, NV 89014; telephone (702) 818-5898 as the agent of the Filer upon whom may be served any process, pleadings, subpoenas, or other papers in: 

     

    (a)any investigation or administrative proceeding conducted by the Commission; and 

     

    (b)any civil suit or action brought against the Filer or to which the Filer has been joined as defendant or respondent, in any appropriate court in any place subject to the jurisdiction of any state or of the United States, or of any of its territories or possessions or of the District of Columbia, where the investigation, proceeding or cause of action arises out of or relates to or concerns (i) any offering made or purported to be made in connection with the securities registered or qualified by the Filer on Form 20-F on June 14, 2024, July 27, 2024, August 14, 2024, August 22, 2024 or any purchases or sales of any security in connection therewith; (ii) the securities in relation to which the obligation to file an annual report on Form 40-F arises, or any purchases or sales of such securities; (iii) any tender offer for the securities of a Canadian issuer with respect to which filings are made by the Filer with the Commission on Schedule 13E-4F, 14D-1F or 14D-9F; or (iv) the securities in relation to which the Filer acts as trustee pursuant to an exemption under Rule 10a-5 under the Trust Indenture Act of 1939. The Filer stipulates and agrees that any such civil suit or action or administrative proceeding may be commenced by the service of process upon, and that the service of an administrative subpoena shall be effected by service upon such agent for service of process, and that the service as aforesaid shall be taken and held in all courts and administrative tribunals to be valid and binding as if personal service thereof had been made. 

     

    F.The Filer stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time until six years have elapsed from the date of the last sale of securities in reliance upon the Regulation A exemption. 

     

    The Filer further undertakes to advise the Commission promptly of any change to the Agent's name or address during the applicable period by amendment of this form, referencing the file number of the relevant form in conjunction with which the amendment is being filed.

     

    G.The Filer undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish promptly, when requested to do so by the Commission staff, information relating to: the Form 1-A; the securities to which the Form 1-A relates; and the transactions in such securities 

    .


     

    SIGNATURES

     

    The Filer certifies that it has duly caused this power of attorney, consent, stipulation and agreement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Vancouver, Province of British Columbia, Country of Canada, on March 31, 2025.

     

     

    BIOHARVEST SCIENCES INC.

     

     

     

     

    By:

    /s/ Ilan Sobel

     

    Name:

    Ilan Sobel

     

    Title:

    Chief Executive Officer

     

    This statement has been signed by the following person in the capacity indicated on March 31, 2025.

     

     

    Empire Stock Transfer Inc.

    as Agent for Service of Process for BioHarvest Sciences Inc.

     

     

     

     

    By:

    /s/ Perry Langis

     

    Name:

    Perry Langis

     

    Title:

    Director of Corporate Filings

     

    Get the next $BHST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BHST

    DatePrice TargetRatingAnalyst
    5/5/2025$15.00Buy
    Craig Hallum
    12/18/2024$12.00Buy
    Maxim Group
    More analyst ratings

    $BHST
    SEC Filings

    See more
    • SEC Form 6-K filed by BioHarvest Sciences Inc.

      6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

      5/21/25 2:48:39 PM ET
      $BHST
    • SEC Form 6-K filed by BioHarvest Sciences Inc.

      6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

      5/15/25 4:49:56 PM ET
      $BHST
    • SEC Form 6-K filed by BioHarvest Sciences Inc.

      6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

      5/15/25 4:26:58 PM ET
      $BHST

    $BHST
    Leadership Updates

    Live Leadership Updates

    See more
    • BioHarvest Announces Appointment of Sharon Malka to Board of Directors

      Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the BoardVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately."We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division

      1/22/25 8:30:00 AM ET
      $BHST

    $BHST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound

      First CDMO Project to Utilize In-house AI Tools for Discovery of Plant Cell Targets for the Botanical Synthesis ProcessRehovot, Israel--(Newsfile Corp. - May 21, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's Botanical Synthesis CDMO Services division has secured a new contract to develop a plant-based fragrance compound derived from a plant that is under significant threat due to over harvesting and habitat loss. This agreement is with a new commercial partner targeting the multi-billion-dollar fragrance and scents market.Ahead of the sig

      5/21/25 8:30:00 AM ET
      $BHST
    • Diamond Equity Research Releases Update Note on BioHarvest Sciences Inc. (NASDAQ: BHST)

      New York, May 21, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on BioHarvest Sciences Inc. (NASDAQ:BHST). The update note includes detailed information on the BioHarvest Sciences' financial results, operational updates, business model, management commentary, valuation, and risks. The update note is available below. BioHarvest Sciences May 2025 Update Note  Highlights from the note include:       Q1 Results Surpass Expectations on VINIA Strength and Operating Efficiencies:  BioHarvest Sciences reported robust financial performance for the first quarter of 2025, with rev

      5/21/25 8:00:00 AM ET
      $BHST
    • BioHarvest Sciences Reports First Quarter 2025 Financial Results

      First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceRehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025.First Quarter & Subsequent 2025 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the first quarter of 2025 increased 47% year-over-year to $7.9 million, exceeding management guidance, with gross margins expanding by 227 basis points to 58.

      5/15/25 4:05:00 PM ET
      $BHST

    $BHST
    Financials

    Live finance-specific insights

    See more
    • BioHarvest Sciences Reports First Quarter 2025 Financial Results

      First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceRehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025.First Quarter & Subsequent 2025 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the first quarter of 2025 increased 47% year-over-year to $7.9 million, exceeding management guidance, with gross margins expanding by 227 basis points to 58.

      5/15/25 4:05:00 PM ET
      $BHST
    • BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time

      Rehovot, Israel--(Newsfile Corp. - May 1, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, May 15, 2025 to discuss the Company's first quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:First Quarter

      5/1/25 8:30:00 AM ET
      $BHST
    • BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth Quarter Revenues Grew 62% to $7.3 Million, Exceeding Prior Management Guidance, with Full Year Revenues Increasing 99% Year-Over-Year to $25.2 MillionCDMO Division Secures Anchor Partnership with Tate & Lyle to Develop Next Generation of Plant-Based SweetenersRehovot, Israel--(Newsfile Corp. - March 31, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024.Fourth Quarter 2024 & Subsequent Operational HighlightsAll figures stated in this news release are in U.S.

      3/31/25 4:05:00 PM ET
      $BHST

    $BHST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on BioHarvest Sciences with a new price target

      Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00

      5/5/25 8:30:45 AM ET
      $BHST
    • Maxim Group initiated coverage on BioHarvest Sciences with a new price target

      Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00

      12/18/24 8:10:03 AM ET
      $BHST